The grades of six biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
This week, Biogen Idec (BIIB) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Biogen Idec is a global biotechnology company that meets the needs of therapeutic care providers and recipients. In Portfolio Grader’s specific subcategories of Earnings Growth, Equity and Sales Growth, BIIB also gets A’s. Shares of BIIB have increased 12.6% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of BIIB stock.
Myriad Genetics, Inc. (MYGN) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Myriad Genetics develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage. With a price of $35.03, it is above the 50-day moving average of $25.45. Shares of the stock have been changing hands at an unusually rapid pace, three times the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of MYGN stock.
Regeneron Pharmaceuticals, Inc. (REGN) improves from a C to a B rating this week. Regeneron Pharmaceuticals researches, develops and commercializes therapeutics to treat human disorders and conditions. The stock’s price of $332.78 is above the 50-day moving average of $283.96. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of REGN stock.
BioSpecifics Technologies’ (BSTC) ratings are looking better this week, moving up to an A from last week’s B. BioSpecifics Technologies is a biopharmaceutical company that has been involved in the development of injectable collagenase for multiple indications. For more information, get Portfolio Grader’s complete analysis of BSTC stock.
Cepheid (CPHD) improves from a C to a B rating this week. Cepheid is a molecular diagnostics company that engages in developing, manufacturing, and marketing integrated systems for testing in the clinical market, as well as for application in legacy biothreat, industrial, and partner markets. With a price of $51.98, it is above the 50-day moving average of $47.38. For more information, get Portfolio Grader’s complete analysis of CPHD stock.
Verastem, Inc. (VSTM) is seeing ratings go up from a C last week to a B this week. Verastem is a biopharmaceutical company which is focused on discovering and developing novel drugs that selectively target cancer stem cells in breast and other cancers along with proprietary companion diagnostics. For more information, get Portfolio Grader’s complete analysis of VSTM stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
